Clinical Site

Miami, Florida, United States

505 recruiting

Showing 119 of 19 trials

Recruiting
Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Arthritis, Psoriatic
MoonLake Immunotherapeutics AG600 enrolled135 locationsNCT06641089
Recruiting
Phase 2

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics500 enrolled5 locationsNCT07459647
Recruiting
Phase 2

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics210 enrolled3 locationsNCT07459660
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled26 locationsNCT06887192
Recruiting
Not Applicable

ContraBand™: Safety & Feasibility Study (RM-20-01)

Heart Failure, Left Sided
Restore Medical Ltd55 enrolled12 locationsNCT05230745
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.370 enrolled65 locationsNCT06540833
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.320 enrolled69 locationsNCT06651567
Recruiting
Phase 2

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.705 enrolled69 locationsNCT06480383
Recruiting
Phase 2

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.570 enrolled60 locationsNCT06701903
Recruiting
Phase 3

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Hidradenitis Suppurativa
MoonLake Immunotherapeutics AG35 enrolled18 locationsNCT06768671
Recruiting
Phase 3

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 3

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

Irritability Associated With Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.174 enrolled39 locationsNCT06706674
Recruiting
Phase 3

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Bipolar Depression
Intra-Cellular Therapies, Inc.384 enrolled59 locationsNCT06372964
Recruiting
Phase 3

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

Irritability Associated With Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.174 enrolled37 locationsNCT06690398
Recruiting
Phase 3

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder
Intra-Cellular Therapies, Inc.470 enrolled60 locationsNCT05850689
Recruiting
Phase 3

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

Bipolar Disorder, Manic
Intra-Cellular Therapies, Inc.350 enrolled42 locationsNCT06462586
Recruiting
Phase 3

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

Bipolar Disorder, Manic
Intra-Cellular Therapies, Inc.350 enrolled35 locationsNCT06462612
Recruiting
Phase 2

Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

Parkinson Disease
Intra-Cellular Therapies, Inc.132 enrolled31 locationsNCT05766813